LONDON MARKET CLOSE: Stocks slide in choppy trade as trade war deepens
(Alliance News) - The FTSE 100 resumed its downward path on Wednesday, as China hit back against US tariffs, while a volatile bond market added to the nervous mood. Read More
Price | 10,124.00p on 18-04-2025 | at 04:45:07
---|---|
Change | 0.00p 0% |
Buy | 10,184.00p |
Sell | 10,182.00p |
Buy / Sell AZN Shares |
Last Trade: | Sell 64.00 at 10,124.00p |
Day's Volume: | 0 |
Last Close: | 10,124.00p |
Open: | 0.00p |
ISIN: | GB0009895292 |
Day's Range | 0.00p - 0.00p |
52wk Range: | 9,574.00p - 13,338.00p |
Market Capitalisation: | £156,940m |
VWAP: | 0.00p |
Shares in Issue: | 1,550m |
Astrazeneca (AZN) Latest Trades |
||||
Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
---|---|---|---|---|
Sell* | 64 | 10,124.00p | SI Trade Suspected SELL Trade |
16:50:53 - 17-Apr-25 |
Sell* | 1,700 | 10,130.62059p | SI Trade Suspected SELL Trade |
16:42:08 - 17-Apr-25 |
Sell* | 137,279 | 10,124.00p | Negotiated Trade |
16:36:10 - 17-Apr-25 |
Unknown* | 1,705 | 10,124.00p | OTC Trade |
16:35:24 - 17-Apr-25 |
Unknown* | 66 | 10,124.00p | OTC Trade |
16:35:24 - 17-Apr-25 |
Unknown* | 24 | 10,124.00p | OTC Trade |
16:35:24 - 17-Apr-25 |
Unknown* | 176 | 10,124.00p | OTC Trade |
16:35:24 - 17-Apr-25 |
Unknown* | 165 | 10,124.00p | OTC Trade |
16:35:24 - 17-Apr-25 |
Unknown* | 331 | 10,124.00p | OTC Trade |
16:35:24 - 17-Apr-25 |
Unknown* | 32 | 10,124.00p | OTC Trade |
16:35:24 - 17-Apr-25 |
Astrazeneca (AZN) Regulatory News |
||
Date | Source | Headline |
---|---|---|
11th Apr 2025 5:30 pm | RNS | Result of AGM |
4th Apr 2025 7:05 am | RNS | Imfinzi approved in EU for AEGEAN |
4th Apr 2025 7:00 am | RNS | Enhertu approved in EU in post-ET breast cancer |
1st Apr 2025 3:00 pm | RNS | Total Voting Rights |
31st Mar 2025 7:05 am | RNS | Calquence recommended for EU approval in 1L MCL |
31st Mar 2025 7:00 am | RNS | Imfinzi approved in the US for bladder cancer |
21st Mar 2025 10:58 am | RNS | AZN invests $2.5bn in Beijing R&D & manufacturing |
17th Mar 2025 7:10 am | RNS | Eneboparatide Phase III trial met primary endpoint |
17th Mar 2025 7:05 am | RNS | Imfinzi approved in EU for limited-stage SCLC |
17th Mar 2025 7:00 am | RNS | AstraZeneca to acquire EsoBiotec |